Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Plus WBRT for Brain Metastases in SCLC
NCT07443397Phase 3Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anlotinib in small cell lung cancer (SCLC), brain metastases, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Aug 2025; status: recruiting.
02
Drugs
anlotinib
03
Conditions
small cell lung cancer (SCLC)brain metastases
Beyond the preview
Go deeper on NCT07443397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07443397.